Trials / Completed
CompletedNCT02289924
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
PERSEUS-IT. A Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept (Eylea®) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 912 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in routine clinical practice in Italy for a study population of "naïve" patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Administration by intravitreal injection |
Timeline
- Start date
- 2015-01-09
- Primary completion
- 2019-03-28
- Completion
- 2019-07-08
- First posted
- 2014-11-13
- Last updated
- 2023-11-07
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02289924. Inclusion in this directory is not an endorsement.